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Among the disciplines of medicine, the study of neurological disorders is particularly challenging. The funda-
mental inaccessibility of the human neural types affected by disease prevents their isolation for in vitro
studies of degenerative mechanisms or for drug screening efforts. However, the ability to reprogram readily
accessible tissue from patients into pluripotent stem (iPS) cells may now provide a general solution to this
shortage of human neurons. Gradually improving methods for directing the differentiation of patient-specific
stem cells has enabled the production of several neural cell types affected by disease. Furthermore, initial
studies with stem cell lines derived from individuals with pediatric, monogenic disorders have validated
the stem cell approach to disease modeling, allowing relevant neural phenotypes to be observed and
studied. Whether iPS cell-derived neurons will always faithfully recapitulate the same degenerative
processes observed in patients and serve as platforms for drug discovery relevant to common late-onset
diseases remains to be determined.Introduction
The American physicist Richard Feynman was accredited with
the assertion, ‘‘What I cannot create, I do not understand.’’
When translated into the context of neurological disease, Feyn-
man’s statement could be considered an explicit challenge. If
sufficient progress has been made toward deciphering the
genetic and cellular basis of neural degeneration, then it should
be possible to take the resulting knowledge and apply it to the
development of accurate models for neurological disease. To
date, such efforts have beenmet with greatest success in animal
models for diseases of the nervous system.
Unquestionably, modeling of neurological diseases in geneti-
cally manipulated animals has led to important advances in the
understanding of pathogenic mechanisms, in particular those
relevant to neurodevelopmental and neurodegenerative disor-
ders. These animal models, particularly rodent models, have
become ‘‘workhorses’’ for both mechanistic studies and drug
discovery. While the continued importance of animals in transla-
tional research is indisputable, genetic and anatomical variation
between rodents and man have led to imperfect phenotypic
correlations among genetic models and the human diseases
they attempt to recapitulate. Furthermore, most neurodegenera-
tive diseases are sporadic in etiology, arising from what appear
to be the complex interactions of genetic and environmental
risk factors. As a result, it may be difficult or impossible to fully
model these conditions in animals. But perhaps most notably,
preclinical successes in the treatment of existing animal models
have not translated well into clinical benefits for patients. Thus
there must be aspects of neurological disease that we do not
understand well enough to recapitulate.
It is possible that an improved understanding of many neuro-
logical diseases could be developed if there were accurate
cellular models of these conditions that relied only on actual626 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.patient genotypes and resulted in degeneration of the disease
affected human neural types in vitro. If such cellular models of
neural degeneration could be reconstituted and studied in
concert with existing animal models, it is possible that improved
outcomes for patients might eventually result. However, to date,
attempts to develop in vitro models for nervous system degener-
ation have been stymied by the fundamental inaccessibility of
many specific human neural subtypes.
While peripheral nerves or muscle are sometimes clinically ac-
cessed for pathological studies, routine sampling of tissue from
the brain and spinal cord of living patients are usually only per-
formed in rare conditions where a tissue diagnosis is necessary
for subsequent clinical management. Thusmost neural cell types
cannot be accessed in any quantity from living patients.
Although postmortem samples from the nervous system can
be obtained, such tissue is ravaged by end-stage manifestations
of disease. While neuropathological samples can be helpful at
times in making a specific diagnosis, they have not always
proven useful for revealing how the neurological disease process
unfolds over time. Even if the routine sampling of neurons directly
from patients were possible, an inability to expand and study
these postmitotic cells in vitro for prolonged periods would
further diminish their utility.
However, recent advances in the areas of stem cell and re-
programming biology now seem to provide a novel route to the
generation of a wide variety of neural types for studying neuro-
logical disease. New ‘‘stem cell’’ models of disease provide an
emerging and exciting opportunity to test Feynman’s assertion
of whether or not we ‘‘understand’’ enough concerning the
underlying causes of neurological disease to accurately ‘‘create’’
neurodegenerative processes in vitro. Here we review emerging
efforts to use stem cell and reprogramming approaches to
produce specific human neural subtypes carrying patient
Figure 1. Prospects of Using Human Pluripotent Stem Cells for Disease Modeling and Drug Discovery
Disease and patient-specific pluripotent stem cells can be derived from several sources.
(A) Embryonic stem (ES) cells can be derived from donated embryos identified to carry a disease-causing genetic mutation discovered through preimplantation
genetic diagnosis (PGD). However, ES cells fromdiseasedPGD embryos are a scarce resource and lack correlative information of disease onset and progression.
(B) Pluripotent stem cells can also be derived through defined factor reprogramming of readily obtainable somatic cells from patients with a neurological disease,
with or without known genetic mutations. Typically, skin fibroblasts obtained from patients are the donor somatic cell type used for reprogramming, though
virtually any cell type can be used.
(C) Pluripotent stem cells are expanded in culture and directed to differentiate into cell types important for a particular disease.
(D) Neurons and other neural cell types are studied over time in vitro and, depending on the disease process of interest, can be evaluated for defects in neu-
rogenesis, migration, morphology, synaptic connectivity, survival, and electrophysiological function. Aberrant protein aggregation and non-cell-autonomous
factors can also be tested.
(E) Once disease-relevant cellular phenotypes are identified, rescue experiments can be performed to help validate the disease model and assays developed for
drug discovery. Neural cells and other clinically important cell types such as cardiomyocytes and hepatocytes obtained through thesemethodsmay also be used
for studies on predictive toxicology (further discussed in text).
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hallmarks of disease-specific degenerative processes.
As we will describe, when stem cells are combined with
methods that direct their differentiation along the lineages
leading to the neuronal types principally affected in a given
neurological disease, this new resource now provides exciting
opportunities for disease modeling, drug discovery, predictive
toxicology, and transplantation therapy (Figure 1). The implicit
promise of this technology is that patient-derived iPS cells may
offer unprecedented opportunities to study the developmental
progression of a neurological disease process in vitro. While
the full potential of this approach is only beginning to be realized,
initial attempts to use it for the modeling of several neurological
disorders have provided the proof of principle that further insight
into more complex disorders may be possible.
Toolkit for Neurological Disease Modeling
using iPS Cells
Generation of Patient-Specific iPS Cells
Human pluripotent stem cells are characterized by the ability to
renew indefinitely in culture while retaining their capacity todifferentiate into most, if not all, cell types (Yu and Thomson,
2008). This differentiation potential includes the ability to
produce previously inaccessible cell types from the nervous
system, which has obvious implications for the study and treat-
ment of neurological disease. Human embryonic stem (hES)
cells are pluripotent stem cells derived from the inner cell
mass of the blastocyst-stage embryo. These preimplantation
embryos generally exist in excess of clinical need at in vitro
fertilization (IVF) clinics and are donated to research by individ-
uals under informed consent (Chen et al., 2009; Cowan et al.,
2004; Thomson et al., 1998). Of particular interest for the study
of neurological disease are stem cell lines produced from
embryos discarded after preimplantation genetic diagnosis
(PGD) because they were identified to carry disease-associated
mutations. Such stem cell lines would in turn be expected to
carry the disease genes responsible for the condition and could
prove useful for mechanistic studies. To date, a very small
number of hES cell lines harboring known mutations for a few
monogenic neurological disorders have been established (Eiges
et al., 2007; Mateizel et al., 2006, 2010). This scarcity of PGD
stem cell lines is partly due to the small number of embryosNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 627
Table 1. Published Patient-Specific iPS Cell Lines of Interest to Clinical Neurosciences
Disease Gene (mutation)
Donor
Cell
Reprogramming
Method
Reported Disease-
Related Phenotype Reference Corresponding Author
Parkinson’s
disease
Idiopathic Fb LV: Cre-excisable,
DOX-inducible;
K,S,O or K,S,O,M
Hargus et al., 2010;
Soldner et al., 2009
jaenisch@wi.mit.edu;
isacson@hms.harvard.
edu
Parkinson’s
disease
LRRK2 (G2019S) Fb RV: K,S,O Increased caspase-3
activation and DA
neuron death with
various cell stress
conditions
Nguyen et al., 2011 tpalmer@stanford.edu;
reneer@stanford.edu
Parkinson’s
disease
PINK1
(Q456X; V170G)
Fb RV: K,S,O,M Impairment
of stress-induced
mitochondrial
translocation of Parkin
in DA neurons
Seibler et al., 2011 dkrainc@partners.org
Huntington’s
disease
HTT
(72 CAG repeats)
Fb RV: K,S,O,M Park et al., 2008a george.daley@
childrens.harvard.edu
Amyotrophic
lateral sclerosis
SOD1 (L144F) Fb RV: K,S,O,M Dimos et al., 2008 eggan@mcb.harvard.
edu
Amyotrophic
lateral sclerosis
SOD1
(L144F; G85S)
Fb RV: K,S,O Boulting et al.,
2011
eggan@mcb.harvard.
edu
Spinal muscular
atrophy, type I
SMN1 deletion Fb LV: S,O,N,L Reduced number
of motor neurons,
decreased soma size,
and synaptic defects
Ebert et al., 2009 ebert@waisman.wisc.
edu; cnsvendsen@
wisc.edu
Friedreich ataxia FXN
(GAA expansion)
Fb RV: K,S,O,M Ku et al., 2010 joelg@scripps.edu
Friedreich ataxia FXN
(GAA expansion)
Fb RV: K,S,O,M Liu et al., 2010 apebay@unimelb.edu.
au
Familial
dysautonmia
IKBKAP
(homozygous
2507+6T > C)
Fb LV: K,S,O,M Defects in
neurogenesis and
migration
Lee et al., 2009 studerl@mskcc.org
Duchenne
muscular
dystrophy
DMD (deletion
of exons 45-52)
Fb RV: K,S,O,M Park et al., 2008a george.daley@
childrens.harvard.edu
Duchenne
muscular
dystrophy
DMD (deletion
of exons 46-50)
Fb LV: Cre-excisable,
KSOM
Tchieu et al., 2010 kplath@mednet.ucla.
edu
Becker muscular
dystrophy
Unidentified Fb RV: K,S,O,M Park et al., 2008a george.daley@
childrens.harvard.edu
Rett syndrome MeCP2 (1155 del32;
Q244X)
Fb RV: K,S,O,M Defects in neuronal
morphology,
synapses, and
electrophysiological
function
Marchetto et al.,
2010
muotri@ucsd.edu
Rett syndrome MeCP2
(D exon 3-4; T158M)
Fb RV: K,S,O,M Reduced neuronal
soma size
(d exon 3-4 line)
Cheung et al., 2011 jellis@sickkids.ca
Rett syndrome MeCP2 (R306C) Fb RV: K,S,O,M Hotta et al., 2009 jellis@sickkids.ca
Gaucher disease GBA (AAC > AGC,
exon 9, G-insertion,
nucleotide 84 of
cDNA)
Fb RV: K,S,O,M Park et al., 2008a george.daley@
childrens.harvard.edu
Lesch–Nyhan
syndrome (carrier)
Heterozygosity
of HPRT1
Fb LV: Dox-inducible,
K,S,O,M,N
Park et al., 2008a george.daley@
childrens.harvard.edu
Down syndrome Trisomy 21 Fb RV: K,S,O,M Park et al., 2008a george.daley@
childrens.harvard.edu
628 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.
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Table 1. Continued
Disease Gene (mutation)
Donor
Cell
Reprogramming
Method
Reported Disease-
Related Phenotype Reference Corresponding Author
Fragile-X
syndrome
FMR1 Fb RV: K,S,O,M Urbach et al., 2010 george.daley@
childrens.harvard.edu;
nissimb@cc.huji.ac.il
Angelman
syndrome
maternally inherited
deletions of
chr. 15q11-q13
Fb RV: K,S,O,M,L Chamberlain et al.,
2010
chamberlain@uchc.
edu; lalande@uchc.edu
Prader-Willi
syndrome
paternal deletion
of chr.15q11-q13
Fb RV: K,S,O,M,L Chamberlain et al.,
2010
chamberlain@uchc.
edu; lalande@uchc.edu
Schizophrenia Unidentified Fb LV: Dox-inducible,
K,S,O,M, L
Reduced neurites and
synaptic connectivity
Brennand et al.,
2011
gage@salk.edu
Schizophrenia DISC1 (4 bp deletion
at the exon-intron
12 region)
Fb Episomal,
nonintegrating,
DNA plasmids,
various
combination
of factors
Chiang et al., 2011 shongju1@jhmi.edu;
rmargolis@jhmi.edu;
gming1@jhmi.edu
Fibroblast (Fb), KLF4 (K), SOX2 (S), OCT4 (O), c-MYC (M), N:NANOG (N), LIN28 (L), retrovirus (RV), lentivirus (L), dopamine (DA).
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carried out for a select number of monogenic neurological
disorders. Alternatively, disease-causing mutations can be
introduced into human ES cell lines by homologous recombina-
tion (Urbach et al., 2004). Unfortunately, disease-specific PGD
embryos, as a resource, are limited in number and producing
disease-specific ES cell lines by homologous recombination is
highly inefficient. In addition, in both cases, these approaches
do not allow for the modeling of sporadic disease or for corre-
lations to be made between in vitro cellular phenotypes and
clinical observations made over the lifetime of the patient.
Another approach for using hES cell lines for disease modeling
is to genetically modify them to express a disease-causing
transgene using cell-type-specific promoters (Karumbayaram
et al., 2009a). However, this approach would again only be
useful for modeling monogenic diseases caused by highly
penetrant mutations and not for modeling complex disorders
for which genetic determinants are either unknown or poorly
understood.
In contrast, the ‘‘reprogramming’’ of somatic cells allows the
production of induced pluripotent stem (iPS) cells, which
possess all of the salient characteristics of ES cells. These iPS
cells can be generated using readily accessible tissue from
patients with any condition. The obvious advantage of such an
approach is that patient-specific iPS cells carry the precise
genetic variants, both known and unknown, that contributed to
disease, residing in the context of the patient’s own genetic
background. Thus, any cellular phenotypes observed could be
correlated with clinical benchmarks such as rate of disease
progression. Additionally, patient-specific iPS cells may eventu-
ally serve as a customizable resource for personalized regener-
ative medicine, drug testing, and predictive toxicology studies.
Since the initial derivations of patient-specific iPS cell lines (Di-
mos et al., 2008; Park et al., 2008a), there has been a dramatic
expansion in the number of diseases for which cell lines have
now been created (Table 1).The approach of induced pluripotency by defined factors has
emerged as an alternative method for the derivation of human
pluripotent stem cells that overcomes many of the limitations
associated with the derivation and manipulation of hES cells. In
2006, Shinya Yamanaka’s group demonstrated that the
combined ectopic expression of the transcription factors Oct4,
Sox2, Klf4, and c-Myc was sufficient to reprogram mouse fibro-
blasts into what were termed induced pluripotent stem cells, or
simply iPS cells (Takahashi and Yamanaka, 2006). Shortly there-
after this approach was recapitulated using human fibroblasts,
resulting in the generation of human iPS cells (Lowry et al.,
2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al.,
2007). Subsequent studies have now demonstrated that iPS
cells can be generated, albeit with lower efficiency, using only
three factors (OCT4, SOX2, and KLF4) (Nakagawa et al., 2008).
Human iPS cells have very similar properties to hES cells.
These include similarities in their morphology, proliferation rate,
gene expression profiles, and capacity to differentiate into
various cell types of the three embryonic germ layers in vitro.
This differentiation potential can be manifested through a variety
of methods. These include in vitro approaches such as differen-
tiation in cell aggregates called embryoid bodies (EBs), and
in vivo strategies, including the formation of teratomas, which
are benign tumors formed after injection of the stem cells into
immunodeficient mice (Lowry et al., 2008; Park et al., 2008b; Ta-
kahashi et al., 2007; Yu et al., 2007).
Induced pluripotency by defined factors has made possible
the generation of patient-specific iPS cells (Table 1). Because
of the relative ease with which iPS cells can be generated from
accessible human tissue, such as fibroblasts from a skin biopsy,
the derivation of iPS cell lines from patients suffering from
a variety of diseases has become increasingly routine. Many
iPS cell lines have now been produced for a variety of neurolog-
ical diseases including amyotrophic lateral sclerosis (ALS)
(Boulting et al., 2011; Dimos et al., 2008), Huntington’s disease
(HD) (Park et al., 2008a), spinal muscular atrophy (SMA) (EbertNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 629
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et al., 2008a; Seibler et al., 2011; Soldner et al., 2009), familial
dysautonomia (Lee et al., 2009), and Rett syndrome (Cheung
et al., 2011;Marchetto et al., 2010). Because of their defining plu-
ripotency property, these iPS cells can be differentiated in vitro
into any desired cell type, including those specifically affected
in a particular neurological disorder, such as spinal motor
neurons for the study of SMA and ALS (Boulting et al., 2011; Di-
mos et al., 2008; Ebert et al., 2009).
Thus far, the majority of reported iPS cell lines have been
generated using viral transduction of vectors that encode re-
programming transcription factors. This approach results in
multiple genomic integrations of the viral transgenes. While the
potential for mutagenesis and tumorigenicity that result from
these insertions may preclude the use of ‘‘first-generation’’ iPS
cell lines for transplantation medicine (Okita et al., 2007), early
proof-of-principle studies indicate that they are probably
adequate for disease-modeling purposes (Ebert et al., 2009;
Lee et al., 2009; Marchetto et al., 2010).
However, newer strategies for reprogramming are rapidly
emerging and some of these allow for the derivation of geneti-
cally unmodified human iPS cells (reviewed in Gonza´lez et al.,
2011). These novel reprogramming approaches include the use
of nonintegrating RNA viruses (Fusaki et al., 2009) or episomal
vectors (Yu et al., 2009), the delivery of excisable lentiviral or
transposon vectors (Kaji et al., 2009; Soldner et al., 2009), the
transduction of the reprogramming proteins modified for cellular
uptake (Kim et al., 2009), and the direct delivery of synthetic
mRNAs modified to escape the endogenous antiviral cell
response (Warren et al., 2010). In addition, small molecules
can be used to increase the reprogramming efficiency or to
replace the activity of one or more of the reprogramming factors
(Huangfu et al., 2008; Li et al., 2009; Lin et al., 2009; Zhu et al.,
2010). However, the generation of iPS cells by using only small
molecules has yet to be reported. Thus, the ultimate method in
deriving disease-specific iPS cell lines will depend on their
downstream use.
As a cautionary note, it is important to mention that there have
been reports indicating differential gene expression and DNA
methylation patterns in hES cells and hiPS cells (Chin et al.,
2009; Doi et al., 2009; Lister et al., 2011). However, it is not yet
clear what the consequences of this variation are upon stem
cell differentiation or functionality of the resulting cell types, if
any. Froma neurological disease-modeling point of view, it might
be more relevant to determine whether hES cells and hiPS cells
differ in their ability to reliably generate the differentiated neural
cell type(s) of interest. Two recent studies, including one from
our group, compared human ES and hiPS cell lines in terms of
their capacity to generate functional motor neurons (Boulting
et al., 2011; Hu et al., 2010). While both studies found variable
differentiation efficiency among individual iPS cell lines, Hu and
colleagues reported that iPS cell differentiation capacity toward
motor neurons was significantly reduced compared to that of
hES cells (Hu et al., 2010), whereas our group found a similar
range of differentiation efficiencies when a much larger number
of hES and hiPS cell lines were analyzed (Boulting et al., 2011).
Our experience suggests that each pluripotent stem cell line,
regardless of whether it is an iPS cell or hES cell line, has its630 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.own discrete properties that must be taken into consideration
when using it for directed differentiation in disease-modeling
studies. Recently, a genomics-based assay has been developed
to rapidly characterize the differentiation potential of pluripotent
stem cell lines that may aid in predicting the best lines to move
forward for neurological applications (Bock et al., 2011). Further-
more, analyses of chromosomal aberrations (Mayshar et al.,
2010), subchromosomal copy-number variation (Hussein et al.,
2011; Laurent et al., 2011), protein-coding point mutations
(Gore et al., 2011), and DNA methylation profiles (Lister et al.,
2011) indicate that hiPS cells can exhibit genetic and epigenetic
abnormalities, which can result from the reprogramming process
itself or, as with hES cells (Baker et al., 2007), from their adapta-
tion to long-term in vitro culture.While the functional implications
of these alterations remain to be elucidated, in the context of
disease modeling they underscore the importance of using
more than one iPS cell line per patient and control, as well as
multiple disease and control genotypes. This would minimize
the possibility that phenotypic differences resulting from
genomic or epigenetic instability in iPS cells are incorrectly
presumed to be relevant to the disease model.
Differentiation of Human Pluripotent Stem Cells into
Disease-Relevant Neural Cell Types
A critical component of neurological disease modeling using
human pluripotent stem cells is the availability of reliable proto-
cols that can efficiently direct stem cell differentiation into the
specific neural cell types affected in disorders of interest
(Figure 2). Insights into inductive pathways that drive neural
differentiation have been gained from early studies of mouse,
chick, and Xenopus embryos. Knowledge of these pathways
has informed rational approaches now routinely used to direct
the differentiation of pluripotent stem cells in vitro (reviewed in
Gaspard and Vanderhaeghen, 2010; Murry and Keller, 2008;
Peljto and Wichterle, 2011; Schwartz et al., 2008). The first
step in most protocols is the differentiation of the pluripotent
stem cells into a population of neural progenitors. This initial
‘‘neural induction’’ step can be accomplished by using sponta-
neous differentiation, stromal feeder coculture, treatment with
retinoic acid, or culture in definedmedia containing themitogens
FGF2 and EGF2 (Joannides et al., 2007; Murry and Keller, 2008).
More efficient neural induction of human ES and iPS cells can be
achieved by dual inhibition of Activin/Nodal/TGF-b and BMP
signaling using recombinant endogenous inhibitors or small-
molecule antagonists (Chambers et al., 2009; Smith et al.,
2008; Zhou et al., 2010). These neural progenitors can then be
patterned along the rostro-caudal and dorso-ventral axes using
specific morphogens and growth factors (Figure 2).
Much as in the embryo, it appears that a variety of neural
phenotypes can be obtained, depending on the combination
and timing of the inductive signals to which progenitors are
exposed. Disease-relevant neural cell types that have been
generated in vitro by directed differentiation of human pluripo-
tent stem cells include spinal motor neurons (Boulting et al.,
2011; Dimos et al., 2008; Hu and Zhang, 2009; Lee et al.,
2007b; Li et al., 2005), midbrain dopaminergic neurons (Cham-
bers et al., 2009; Cho et al., 2008; Hargus et al., 2010; Nguyen
et al., 2011; Roy et al., 2006), basal forebrain cholinergic neurons
(Bissonnette et al., 2011), cortical progenitors (Eiraku et al.,
Figure 2. Directed Neural Differentiation of Human Pluripotent Stem Cells
Various methods of neural induction of pluripotent stem cells have been described such as embryoid body formation, retinoic acid treatment, stromal feeder
cocultures, or defined media containing mitogens FGF2 and EGF. Inhibition of TGFb signaling using various molecules enhances neuralization. Defined
combinations of morphogens, small molecules, growth factors, or transcription factors have been shown to specify neural progenitors to certain subtypes of
neurons as well as glial cells. Some of the best-characterized pathways of clinically important cell types are illustrated above and described in the main text.
Efficient methods to produce astrocytes have yet to be determined.
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Keirstead et al., 2005; Nistor et al., 2005). In addition, neural crest
cell derivatives including sensory neurons and Schwann cells
can also be generated (Lee et al., 2010).
One of the first directed differentiation methods to be devel-
oped is that for the production of spinal motor neurons. Using
two developmentally relevant morphogens, retinoic acid (RA)
and Sonic hedgehog (Shh), Wichterle and colleagues showed
that mouse ES cells could be directed to differentiate into func-
tional spinal motor neurons (Wichterle et al., 2002). RA induces
neuralization and caudalization of stem cells, while the ventraliz-
ing activity of Shh converts spinal progenitor cells to motor
neurons (Peljto and Wichterle, 2011; Wichterle et al., 2002). RA
treatment and induction of SHH signaling have also been used
to derive functional spinal motor neurons from human pluripotent
stems cells (Boulting et al., 2011; Dimos et al., 2008; Hu and
Zhang, 2009; Karumbayaram et al., 2009b; Lee et al., 2007b; Li
et al., 2005). Lee and colleagues demonstrated the in vivo poten-
tial of hES cell-derived spinal motor neurons using transplanta-
tion assays into the spinal cord of developing chick embryos
and of adult rats (Lee et al., 2007b). Both approaches yielded
robust engraftment and maintenance of motor neuron pheno-
type and, when transplanted in developing chick spinal cord,
were capable of forming long axonal projections to skeletal
muscle (Lee et al., 2007b).
Beyond its caudalizing role on neural progenitors, RA signaling
also affects spinal motor neuron subtype specification byimposing a rostral cervical identity (Peljto and Wichterle, 2011;
Wichterle et al., 2002). Using inhibition of Activin/Nodal signaling
for neural induction, functional human spinal motor neurons
could also be specified in a retinoid-independent pathway,
which results in the production of more posterior motor neuron
types (Patani et al., 2011). As disorders like ALS selectively target
certain subtypes and pools of motor neurons (Kanning et al.,
2010), the ability to direct the differentiation of stem cells into
specific motor neuron subtypes could have important implica-
tions for disease modeling and studies aiming to understand
mechanisms of selective vulnerability.
Another clinically relevant neuronal subtype that has been
generated in vitro from human pluripotent stem cells is midbrain
dopaminergic (DA) neurons, which are preferentially affected in
PD. Several studies on the controlled differentiation of hES and
hiPS cells into populations of neurons expressing tyrosine
hydroxylase have been reported (Ben-Hur et al., 2004; Cham-
bers et al., 2009; Cho et al., 2008; Cooper et al., 2010; Hargus
et al., 2010; Perrier et al., 2004; Roy et al., 2006; Soldner et al.,
2009; Yan et al., 2005). Most of these differentiation strategies
rely on the patterning of neural progenitors by the combined
activity of SHH and FGF8, first shown to have a significant effect
on dopaminergic differentiation by seminal work of Lee and
colleagues using mouse ES cells (Lee et al., 2000). Methodolog-
ical improvements to enhance human dopaminergic differentia-
tion in vitro include coculture with immortalized human fetal
astrocytes (Roy et al., 2006), derivation and expansion ofNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 631
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(Cho et al., 2008), and dual inhibition of BMP/TGF-b signaling
during neural induction (Chambers et al., 2009). The in vivo func-
tionality of human DA neurons derived from hES cells (Ben-Hur
et al., 2004; Cho et al., 2008; Roy et al., 2006) and hiPS cells (Har-
gus et al., 2010) has been demonstrated by transplantation
assays into the striatum of 6-hydroxydopamine-lesioned parkin-
sonian rats showing partial recovery of motor function. A recent
study reported the controlled differentiation of hES cells to basal
forebrain cholinergic neurons (BFCN), the neuronal subtype pref-
erentially affected in Alzheimer’s disease (AD) and associated
with cognitive decline (Bissonnette et al., 2011; Mesulam et al.,
2004). Bissonnette and colleagues devised two strategies for
the generation of a predominantly pure population of BFCN
from hES cell-derived neural progenitors. While one method
relied on the use of the diffusible ligand BMP9, the other strategy
involved the transgenic overexpression of two developmentally
relevant transcription factors, Lhx8 and Gbx1, which were
further shown to act downstream of BMP9 signaling (Bisson-
nette et al., 2011). hES cell-derived BFCNs were shown to stably
engraft into murine hippocampal slice cultures and to generate
electrophysiologically functional cholinergic synapses (Bisson-
nette et al., 2011).
In addition to various neuronal subtypes, neural progenitors
obtained from human pluripotent stem cells are also capable
of giving rise to glial cell types of the CNS, astrocytes and oligo-
dendrocytes (Zhang et al., 2001). When neural differentiation
cultures are maintained for several weeks, cells with molecular
characteristics of astrocytes (GFAP+ and S100b+ cells) can be
detected (Johnson et al., 2007; Zhang et al., 2001). However,
directed differentiation protocols and functional characterization
of astrocytes derived from human ES or iPS cells have yet to be
reported. In contrast, there are already a number approaches for
the efficient directed differentiation of human oligodendrocytes
and their progenitors from hES cells (Hatch et al., 2009; Hu
et al., 2009; Kang et al., 2007; Keirstead et al., 2005; Nistor
et al., 2005). The ability of these differentiated cells to myelinate
axons has been demonstrated both in vitro by coculture with rat
hippocampal neurons (Kang et al., 2007) and in vivo by trans-
plantation into the shiverermouse model of dysmyelination (Nis-
tor et al., 2005). Furthermore, preclinical studies evaluating hES
cell-derived oligodendrocyte progenitor cell (OPC) transplants
into adult rats have reported improvement of locomotor recovery
in both thoracic and cervical spinal cord injury (SCI) models
(Keirstead et al., 2005; Sharp et al., 2010). These studies have
been translated into the first clinical trial using hES cell-based
therapy, which was initiated by Geron Corporation and currently
a phase I safety study of hES cell-derived OPCs administered to
patients with neurologically complete, subacute SCI (http://
clinicaltrials.gov/).
Neural progenitors generated in vitro can also be directed
toward cell types of the peripheral nervous system. Lee and
colleagues demonstrated that human ES cells could be used
to derive neural crest (NC) precursors that in turn could be
directed to differentiate into peripheral neurons and Schwann
cells, among other NC derivatives (Lee et al., 2007a). NC precur-
sors derived from hES cells were also able to survive and differ-
entiate in vivo upon transplantation into developing chick632 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.embryos and adult immunodeficient mice (Lee et al., 2007a).
More recently, protocols for the prospective purification and
propagation of NC cells derived from both hES and hiPS cells
have also been reported (Lee et al., 2010).
Case Studies in iPS Cell Neurological Disease Models
Although a good deal of progress continues to bemade in devel-
oping a toolkit for generating iPS cells and directing their differ-
entiation along specific lineages, early studies of neurons made
from iPS cells have begun to move forward. Thus far, only a few
hiPS cell models of neurological diseases have yielded
convincing phenotypes. Among these models, disease-related
deficits in cell survival, neuronal morphology, neuronal migra-
tion, synapse formation, and electrophysiological function have
been described. These examples, described below, have
provided the initial ‘‘proof of concept’’ that disease modeling is
possible from disease-specific iPS cells (Figure 3).
Spinal Muscular Atrophy
The first example of using patient-derived iPS cells to model any
human disease was for the study of spinal muscular atrophy
(SMA) (Ebert et al., 2009). SMA is an autosomal-recessive
disease characterized by the selective degeneration of lower
motor neurons in the brainstem and spinal cord, which in turn
leads to progressive muscle atrophy and weakness. SMA is
the leading genetic cause of infant mortality. Clinically, SMA is
classified into distinct subgroups (I–IV) based on several clinical
characteristics including age of onset, ability to attain motor
milestones such as sitting or independent walking, and time to
death (Lunn and Wang, 2008). Type I, the most common form
of the disease, generally sets in before 6 months of life. Infants
have severe muscle weakness, difficulty with sucking and swal-
lowing, tongue fasciculations, and intercostal muscle weakness
leading to profound respiratory difficulties. These children never
acquire the ability to sit up independently and usually die within
their first 2 years of life.
The vast majority of SMA cases are caused by homozygous
mutations, most often a deletion of Survival of Motor Neuron-1
(SMN1). SMN is thought to be a general housekeeping gene
involved in the biogenesis of small nuclear ribonucleoproteins
important for pre-mRNA splicing, but might also have a specific
role in RNA transport in neurons (Burghes and Beattie, 2009).
However, precisely how a deficiency in SMN, a ubiquitously ex-
pressed protein, produces specific degeneration of lower motor
neurons remains unclear (Monani, 2005). In humans, a highly
homologous gene, SMN2, which lies centromeric to SMN1 on
chromosome 5q, partially but poorly compensates for reduced
SMN levels. While five nucleotides, none of which lead to an
amino acid change, differentiate SMN2 from SMN1, SMN2
mRNA, through alternative splicing, results predominantly in
transcripts lacking exon 7, thereby leading to a truncated,
unstable protein (Lorson et al., 2010). Only 10% of the tran-
scripts are translated into functional full-length SMN protein.
As a result, SMN2 normally contributes little to the overall levels
of full-length SMN protein. However, copy numbers of the SMN2
gene in the human genome are variable, ranging from 0 to 4
copies in the genome. Higher SMN2 copy numbers result in
increased full-length protein levels, which correlate with milder
phenotypes in patients (Mailman et al., 2002). As such, current
Figure 3. Patient-Specific iPS Cell Models of Select Neurological Disorders
Several proof-of-concept studies have established the usefulness of iPS cells as models of disease. Diagrammed here are examples from spinal muscular
atrophy (Ebert et al., 2009), familial dysautonomia (Lee et al., 2009), and Rett syndrome (Marchetto et al., 2010). In red are disease phenotypes described in these
iPS cell models. In blue are responses to specific drug treatments. See text for detailed discussions of each of these models.
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overall SMN2 expression or promote exon 7 inclusion (Sendtner,
2010). While transgenic mouse models exist, mice lack SMN2
and homozygous knockout of SMN1 leads to embryonic
lethality, which has necessitated generating transgenic mice
that harbor human SMN2 (Hsieh-Li et al., 2000; Monani et al.,
2000).
To create a patient-specific iPS cell model of SMA, skin fibro-
blasts were obtained from a child with SMA type 1. The subject
was 3 years old at the time of sample collection and had two
copies of SMN2. Fibroblasts from his unaffected mother were
also reprogrammed to iPS cells by lentiviral transduction of
OCT4, SOX2, NANOG, and LIN28 (Ebert et al., 2009). One iPS
clone from the SMA child (iPS-SMA) and the unaffected mother
(WT-iPS) was subsequently used in their studies. As expected,
SMA fibroblasts and iPS cells lacked SMN1 expression, ex-
pressed the alternatively spliced delta exon 7 mRNA, and
demonstrated reduced levels of full-length SMN contributed by
SMN2 expression. Following directed differentiation of iPS cells
to spinal motor neurons, no significant differences in motor
neuron numbers were seen after a total of 4 weeks of in vitro
differentiation. At 6 weeks, the total numbers of neurons, based
on the overall number of cells positive for neuronal marker TUJ1,
were equivalent between WT and SMA (15.78% in WT and
15.55% in SMA). However, when cultures were specifically eval-
uated for motor neurons based on coexpression of TUJ1 and
ChAT, motor neuron numbers were reduced from the SMA
cultures (4.3% in SMA versus 24.2% in WT). In addition, SMA-
iPS motor neurons were smaller in soma size and synapse
formation appeared to be compromised (Ebert et al., 2009).To demonstrate that SMN production could pharmacologi-
cally be altered in this disease line, two drugs known to increase
SMN production were tested. SMN can be localized to discrete,
punctuate structures called ‘‘gems’’ (Liu and Dreyfuss, 1996).
SMA fibroblasts and iPS cells lacked nuclear SMN gems
whereas gems were detected in WT cells (Ebert et al., 2009).
Treatment with tobramycin or valproic acid, which are know to
increase full-length SMN mRNA by upregulating the SMN2
promoter and activating splicing factors that produce transcripts
containing exon 7 (Brichta et al., 2003; Sumner et al., 2003), led
to increased nuclear gem formation and a 2- to 3-fold increase in
SMN protein expression in SMA-iPS cells (Ebert et al., 2009).
Demonstrating that increased SMN production can occur in
motor neurons derived from SMA-iPS cells and whether this
leads to rescue of themorphological andmotor neuronal specific
survival phenotype shown in this model would clearly be impor-
tant next steps. In addition, similar analysis from additional lines
and patient samples and healthy controls will help clarify the
reproducibility of these phenotypes. It would also be informative
to determine whether variable copy numbers of SMN2, known to
modify the disease severity in patients and phenotypes in mice
models, modify the severity of the iPS-derived motor neuron
phenotypes and would be additional validating steps for this
model. While numerous compounds have been identified in
drug screens that assay for increased SMN production in easily
accessible cell types, motor neurons derived from SMA iPS cells
will provide for relevant assays that could assess potential
phenotypic benefit in motor neuron survival, axonal outgrowth,
and neuromuscular junction numbers. Such an approach would
be more relevant than pharmacological screening using humanNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 633
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toid cell lines (Chang et al., 2001; Sumner et al., 2003). Thus, it
could provide an additional assay to select the most promising
compounds to take forward in SMA clinical trials.
Familial Dysautonomia
Familial Dysautonomia (FD, MIM 223900), also known as Hered-
itary Sensory and Autonomic Neuropathy, Type III (HSAN III) or
Riley-Day Syndrome, is a rare autosomal-recessive disorder
caused by mutations in the I-kB kinase associated protein (IKB-
KAP) gene. FD is primarily a disorder of peripheral sensory and
autonomic neurons, although central neuronal dysfunction is
probably also involved. FD patients have alterations in pain
and temperature sensitivity, absent deep tendon reflexes, auto-
nomic crises (hypertension, tachycardia, hyperhydrosis),
postural hypotension, GI dysmotility, and cardiovascular and
respiratory disease (Axelrod, 2004). While the constellation of
symptoms can be variable from patient to patient, the clinical
diagnosis is based on several cardinal findings such as the
absence of overflow tears, lingual fungiform papillae, depressed
or absent patellar reflexes, and lack of an axonal flare after intra-
dermal histamine. Patient are almost exclusively of Ashkenazi
Jewish anscestory. Most FD patients do not survive beyond 40
years of age. Pathologically, FD is characterized by reduction
in unmyelinated and small myelinated peripheral axons, loss of
neurons in the dorsal root ganglia, loss of autonomic neurons
in the superior cervical sympathetic ganglia, the parasympa-
thetic sphenopalatine ganglia, and the intermediolateral gray
columns of the spinal cord. While the exact function of the
IKAP protein is not clearly understood in this case, it has been
proposed to serve as a scaffold protein involved in assembling
the holo-Elongator complex. This complex is in turn involved in
RNA polymerase II-mediated transcription elongation and tran-
scriptional regulation of genes, some of which are important in
actin cytoskeletal regulation and cell motility andmigration (Nau-
manen et al., 2008). The causative mutation in over 98% of
patients is a T/ C transition in a donor splice site of intron 20
leading to variable tissue-specific skipping of exon 20 (IVS20 +
6T/ C), causing a frameshift and introduction of a premature
stop codon (Slaugenhaupt et al., 2001). The mutant transcript
is produced in abundant amounts in central and peripheral
neural tissues from patients leading to reduced levels of func-
tional IKAP protein in a tissue-specific manner. The efficiency
of generating the normal, wild-type full length IKBKAP transcript
is especially reduced in sensory and autonomic neurons and
may account for the selective degeneration of these neurons in
patients (Cuajungco et al., 2003).
Using lentiviral transduction of patient-derived fibroblasts with
SOX2, KLF-4, OCT-4, and c-MYC, iPS cell lines from three
patients with FD and unaffected controls were established (Lee
et al., 2009). To evaluate tissue-specific differences in IKBKAP
mRNA expression, iPS cell lines were directed to differentiate
along central and peripheral nervous systems and hematopoi-
etic, endothelial, and endodermal precursor lineages. Using
cell surface markers, each population of lineage-specific cells
was then isolated. Normal IKBKAP expression was found to be
especially reduced in FD-iPS-derived neural crest precursor
cells, consistent with a tissue-specific effect. Comparative tran-
scriptome analysis of FD-iPS cells versus control lines revealed634 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.35 transcripts that were significantly increased and another 54
transcripts that were significantly decreased in disease-specific
cells. Interestingly, the authors reported decreased levels of
transcripts with putative roles in peripheral neurogenesis and
neuronal differentiation. It was also observed that in spontane-
ously differentiating cultures of neural precursor cells, reduced
numbers of TUJ1-positive cells were seen in the FD cultures sug-
gesting a defect in neuronal differentiation. Functional deficits
were also seen. FD neural precursors exhibited a decreased in
migratory behavior in a wound healing in vitro assay and this
defect correlated with a reduction in paxillin positive focal adhe-
sions known to be important for cell spreading and migration
(Lee et al., 2009).
To test whether phenotypes found in this FD-iPS cell model
could be rescued with a candidate drug, the effect of kinetin,
a naturally occurring dietary ingredient and plant hormone was
evaluated. Kinetin had been previously identified from a National
Institute of Neurological Disorders and Stroke compound library
to increase wild-type IKBKAP expression in patient lymphoblas-
toid cell lines (Slaugenhaupt et al., 2004). Furthermore, oral
administration of kinetin to healthy heterozygous patients
increases IKBKAP mRNA expression in lymphocytes (Gold-von
Simson et al., 2009). Kinetin-treated FD-iPS-derived neural
precursor cells resulted in markedly reduced levels of mutant
IKBKAP splice variant and increased the level of normal IKBKAP
(Lee et al., 2009). When added to neural precursor cells in
culture, kinetin failed to ameliorate the defects in neurogenesis
ormigration (Lee et al., 2009). However, when kinetin was contin-
uously given to FD-iPS cells prior to differentiation, a significant
increase in neuron number was seen but the migratory deficit
persisted, suggesting a partial rescue of disease phenotypes.
Nonetheless, the FD-iPS cell model will be a powerful model to
test future therapies as several disease-relevant assays were
described.
Rett Syndrome
Perhaps the most extensive description of disease-related
phenotypes using patient-derived iPS cells is for Rett Syndrome
(RTT, MIM 312750). RTT syndrome is a neurodevelopmental
disorder in the family of autism-spectrum disorders. Classical
RTT is clinically characterized by apparently normal early devel-
opment, followed at 6–18 months by regression of develop-
mentalmilestones, lossof purposeful hand skills, loss of acquired
spoken language, gait abnormalities, and stereotypic hand
movements (Neul et al., 2010). RTT primarily affects girls and is
caused by X-linked mutations in the gene encoding methyl-
CpG binding protein (MeCP2) protein (Amir et al., 1999).
MeCP2 is thought to function as a transcriptional regulator,
both during repression of transcription by interactionswithmeth-
ylated DNA and by recruitment of corepressors and activation of
gene transcription (Adkins and Georgel, 2011). In pathological
tissues, themajor findings are decreased brain size and neuronal
size, reduced dendritic arborizations and spines, and defects in
synaptogenesis (Armstrong, 2005; Shahbazian et al., 2002).
While neuronal-specific expression has been shown in several
human and rodent studies, this view has been more recently
challenged in that glial expression occurs, albeit at lower levels.
It will be critical to resolve this issues as a non-cell-autonomous
astrocytic involvement has been proposed (Ballas et al., 2009).
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factors SOX2, OCT4, c-MYC, and KLF-4 from fibroblasts of
four female RTT patients with distinct MeCP2 mutations along
with non-affected patients (Marchetto et al., 2010). On neural
differentiation, no difference in neuronal survival was observed.
However, examination of neurons in culture at 8 weeks after
differentiation showed a reduced density of VGLUT1 puncta on
glutamatergic neurons, suggesting a glutamate transport defect
in the RTT neurons. Moreover, this phenotype could be recapit-
ulated using shRNA knocking down MeCP2 in unaffected WT-
iPS cell-derived neurons whereas overexpression of MeCP2 in
RTT-iPS and WT-iPS cell neurons increased VGLUT1 puncta,
suggesting that MeCP2 may be involved in regulating glutamer-
gic synapse number. Morphological characterization revealed
reduced numbers of neuritic spines and smaller soma sizes on
RTT neurons. Again, reduced spine density and soma size was
also seen after knockdown with MeCP2 shRNA in WT neurons.
Finally, RTT neuronal cultures showed a decrease in intracellular
calcium oscillations and decreased frequency and amplitude of
spontaneous postsynaptic currents as compared toWT neurons
suggesting functional alterations at the neural network level
(Marchetto et al., 2010).
In this model, promising phenotypic rescue was also demon-
strated pharmacologically. IGF-1 administration led to an
increase in glutamatergic synapse number (Marchetto et al.,
2010). This is in agreement with the finding that systemic infu-
sions of IGF-1 to MeCP2 knockout mice ameliorated several
clinical symptoms and partially reversed reduced dendritic spine
density and EPSC amplitudes (Tropea et al., 2009). Second, use
of the aminoglycoside gentamicin, which has activity in reading-
through of non-sense mutations, led to increased glutamatergic
synapses in iPS cell-derived neurons froma patient with aQ244X
nonsense mutation (Marchetto et al., 2010). However, whether
these pharmacological treatments led to rescue of dendritic
spine density or the electrophysiological abnormalities
described in this model was not shown.
Modeling of X-linked disorders has unique challenges from the
perspective of X chromosome inactivation. Human female iPS
cells, unlike mouse, appear to retain X chromosome inactivation
upon cellular reprogramming, resulting in nonrandom, clonal
populations of iPS lineswith either thematernally or paternally in-
herited X chromosome inactivated (Tchieu et al., 2010). From
a disease-modeling perspective, this phenomenon could be
utilized to identify iPS cell lines that express either the mutant
or wild-type allele, thereby having an isogenic control. This
was recently put to the test in a subsequent Rett iPS cell study.
RTT-iPS cell lines were derived from a female patient with a func-
tionally null mutation inMECP2 from a rearrangement resulting in
deletions of exon 3 and 4 (D3-4) (Cheung et al., 2011). Interest-
ingly, the RTT-iPS cell lines in this study retained an inactive X
chromosome in a nonrandom pattern consistent with other
reports of human iPS cells from females (Tchieu et al., 2010).
By taking advantage of the nonrandompattern of X chromosome
inactivation in several RTT-iPS lines, an isogenic line where the X
chromosome harboring the mutant allele had been inactivated,
thereby resulting in cells expressing only the wild-type MECP2
allele, was identified (Cheung et al., 2011). Upon neural differen-
tiation, the pattern of X chromosome activation was maintainedand lines expressing the mutant allele demonstrated smaller
neuronal soma sizes as compared to the line expressing the
wild-type allele (Cheung et al., 2011). However, more detailed
analysis of phenotypic differences was not described. Thus,
iPS cell disease modeling of X chromosome-linked disorders in
female lines could offer a unique advantage for modeling efforts.
Friedrich’s Ataxia
Friedrich’s Ataxia (FRDA, MIM 229300), an autosomal-recessive
disorder, is the most common inherited ataxic disorder with an
age of onset in the teenage years. Clinical characteristics include
progressive ataxia of gait and limbs, dysarthria, muscle weak-
ness, spasticity in the legs, scoliosis, bladder dysfunction, and
loss of position and vibration sense. Cardiomyopathy and dia-
betesmellitus are systemic complications in some patients (Pan-
dolfo, 2009). FRDA individuals have a GAA triple-repeat expan-
sion in intron 1 of the Frataxin (FXN) gene of greater than 66
repeats whereas normal individuals may have between six and
34 (Campuzano et al., 1996). Pathological expansion of the
GAA triplet leads to transcriptional silencing of FXN, resulting
from heterochromatin formation, adoption of an abnormal
DNA-RNA hybrid structure, or triplex DNA formation (Wells,
2008). Length of GAA expansion correlates with Frataxin defi-
ciency and disease severity and progression (Du¨rr et al., 1996;
Filla et al., 1996). Frataxin is localized to the inner mitochondrial
membrane where it is involved in biogenesis of iron-sulfur clus-
ters and thus in the respiratory chain complex. Frataxin defi-
ciency leads to mitochondrial dysfunction and increased oxida-
tive damage (Pandolfo and Pastore, 2009). Iron accumulation is
seen in affected tissues such as neurons and cardiomyocytes
(Ye and Rouault, 2010).
FRDA-iPS cell lines have been established from patients (Ku
et al., 2010; Liu et al., 2010). While a specific disease-related
phenotype was not reported, the phenomenon of repeat-length
instability that characterizesmany of the repeat expansion disor-
ders could be recapitulated in FRDA-iPS cells (Ku et al., 2010).
Analysis of global gene expression of FRDA-iPS lines (two clones
from two patients) demonstrated that disease lines cluster with
wild-type iPS and ES cell lines but with small differences (5%–
7% global expression difference between FRDA-iPS lines and
WT-iPS/ES lines). Interestingly, analysis of the most differentially
expressed genes had known functions related to mitochondrial
function, DNA repair, and DNA damage.
With regard to GAA repeat instability, iPS cells showed repeat
expansions whereas parental fibroblasts did not (Ku et al., 2010).
Instability was specific to the abnormally expanded FXN as GAA
expansions in WT FXN allele or at two unrelated loci with short
GAA repeats remained unchanged. Repeat length changed
over iPS cell passages in culture. To understand the mechanism
of instability in this iPS cell system, analysis of differences in
mRNA expression showed that MSH2, a critical component of
the DNA mismatch repair (MMR) machinery important for medi-
ating repeat-length instability, was highly expressed in FRDA-
iPS cells relative to donor fibroblasts. shRNA-mediated silencing
of MSH2 resulted in shorter repeat lengths suggesting that FRDA
iPS cells could be a useful system to evaluate themechanisms of
repeat expansions and contractions in disease.
It remains to be shown whether FRDA iPS cells will demon-
strate cell-type-specific expansions of GAA repeats. GAA repeatNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 635
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occurs in various tissues throughout life. For example, large GAA
repeat expansions are especially prominent in the dorsal root
ganglia of FRDA patients, which harbor cell bodies of sensory
neurons, a neuronal subtype especially affected in FRDA (De
Biase et al., 2007). Given FRDA-iPS cells can be directed to
differentiate into sensory neurons, as well as cardiomyocytes,
the presence and mechanisms of tissue-specific expansion
should be testable (Liu et al., 2010).
Perspectives and Future Challenges
Genetic Modification of iPS Cells: Opportunities
for Reporter Lines and Isogenic Controls?
Disease modeling using human pluripotent stem cells might
greatly benefit if the genome of these cells could be readily modi-
fied. For instance, the generation of transgenic ‘‘reporter’’ cell
lines using fluorescent reporter genes under the control of cell-
type-specific promoters could enable the purification, tracking,
and functional characterization of disease relevant cells after
directed differentiation. It is our experience that use of such
reporter genes is a significant consideration. Most in vitro differ-
entiation strategies result in a heterogenous population of differ-
entiated cells, which can include progenitors and a variety of
cellular intermediates. Therefore, having the ability to prospec-
tively identify, purify, and easily track the desired cell type by
means of reporter-gene expression can facilitate downstream
disease-specific assays, which could be hindered by the pres-
ence of other cell types.
The availability of stem cell lines harboring cell-type-specific
reporters could also aid in the improvement of procotols for
the directed differentiation of disease relevant cell types for
which efficient differentiation techniques are not yet available.
In addition, the ability to overexpress or downregulate a partic-
ular gene of interest could be used in the future to recapitulate
or rescue a disease-relevant phenotype. For instance, loss-of-
function monogenic disorders could be mimicked using a wild-
type cell line by downregulation of the particular disease-associ-
ated locus. Conversely, a loss-of-function disease-specific
phenotype could be rescued by overexpression of the wild-
type form of the gene. Finally, the use of gene-targeting strate-
gies to correct or induce a particular genetic defect will allow
for the generation of isogenic lines with and without a disease
genotype. This will be of particular relevance for disease
modeling using patient-specific iPS cell lines, in which
disease-specific phenotypes could be confounded by the vari-
ability inherent to using cell lines of different genetic back-
grounds (discussed further below).
In spite of their self-renewal properties, human ES and iPS
cells can still be difficult to genetically manipulate. Various tech-
niques for stem cell genetic modification have been reported,
and these can result in random (i.e., transgenic) or targeted inte-
gration of the DNA construct (reviewed in Giudice and Trounson,
2008). Transgenic approaches include the use of plasmid trans-
fection (Di Giorgio et al., 2008; Lakshmipathy et al., 2004; Siemen
et al., 2005), lentiviral transduction (Ben-Dor et al., 2006; Xia
et al., 2007), transposases (Lacoste et al., 2009; Wilber et al.,
2007), and bacterial artificial chromosomes (BAC) (Placantona-
kis et al., 2009) as DNA delivery systems.636 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.Each of these strategies is in principal useful for the generation
of both reporter systems and transgenic cell lines that either
overexpress or suppress a given gene of interest. For instance,
our group used plasmid transfection to generate a stable trans-
genic hES cell line that reports via GFP expression on spinal
motor neuron differentiation (Di Giorgio et al., 2008). Placantona-
kis and colleagues used BAC transgenesis of different reporter
constructs to generate hES cell reporter lines that upon neural
differentiation can report for neural stem cell, neuroblast, or
motor neuron lineages (Placantonakis et al., 2009). In another
study, Lacoste and colleagues engineered the piggyBac trans-
posable system to deliver cocktails of doxycycline-inducible
gain and loss-of-function transgenes into hES cells to efficiently
direct their differentiation into neural rosettes (Lacoste et al.,
2009). Some of the limitations associated with transgenic
approaches include the possibility of insertional mutagenesis,
transgene silencing or ectopic expression of the transgene due
to position effects, and lack of faithful expression of a reporter
transgene due to absence of regulatory elements in the promoter
fragment driving its expression (Giudice and Trounson, 2008).
Unlike in mouse embryonic stem cells, where gene targeting
by homologous recombination is routine, human pluripotent
stem cells have proven to be more recalcitrant to this form of
genetic modification. Thus far, only a few studies have reported
the successful targeted genetic modification of human ES cell
lines using conventional approaches (Costa et al., 2007; Davis
et al., 2008; Di Domenico et al., 2008; Irion et al., 2007; Urbach
et al., 2004; Zwaka and Thomson, 2003). Recently, advances
in the design of zinc finger nucleases (ZFNs) have shown
promise for human ES and iPS cell-targeting experiments.
Specific loci have now been disrupted, corrected, and modified
to express reporter genes by means of a ZFN-mediated gene
targeting (DeKelver et al., 2010; Hockemeyer et al., 2009; Lom-
bardo et al., 2007; Zou et al., 2009). ZFNs are engineered hybrid
enzymes composed of DNA binding domains that bind to
specific DNA sequences and a Fok1 nonspecific endonuclease
domain (Klug, 2010). These enzymes can be used to induce
a double-strand break in a specific targeted location in the
human genome, therefore allowing for increase likelihood of
homologous recombination with an additionally provided exog-
enousDNA contruct (Klug, 2010). The fidelity of this system relies
on the specificity provided by the zinc finger DNA binding
domains. Atlhough the selection and validation of ZFNs can be
a costly or laborious process with significant lab expertise
required (Doyon et al., 2008; Isalan et al., 2001; Maeder et al.,
2008; Pearson, 2008), the development of rapid, low-cost, and
user-friendly in silico selection alternatives for designing func-
tional ZFNs has recently been demonstrated (Sander et al.,
2011), which may improve the overall utility of ZFN techonology
for gene-targeting experiments. In the context of hiPS cell
disease modeling, the use of ZFN-mediated targeting to correct
a genetic defect in a patient-specific iPS cell line and in turn
rescue a disease-associated phenotype, remains to be demon-
strated.
Given inherent genetic heterogenity between individuals, the
issue of what constitutes the most appropriate control iPS cell
line for any given patient-derived iPS cell line remains poorly
defined. For single-gene defects, future use of gene-targeted
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will undoubtedly be powerful tools. In addition, as several impor-
tant neurological disorders are caused by gene defects on the X
chromosome, iPS cell lines from females expressing either the
mutant or normal allele based onwhich X chromosome has inac-
tivated could theoretically provide useful phenotypic compari-
sons (see discussion on Rett Syndrome). However, for this
approach to be successful, the dynamics of X chromosome
inactivation in cultured human pluripotent stem cells needs to
be more extensively studied. Apart from these approaches, the
issue of what constitutes the best control line is currently unre-
solved. For monogenetic disorders, it will be necessary to
show that the healthy controls do not harbor the disease-associ-
ated genotype. For example, use of cells from a healthy sibling
who has tested negative for the disease-causing gene mutation,
when available, would constitute a desirable control. For late-
onset neurodegenerative disorders that are relatively common,
the appropriate controls should be from individuals who are
not only ‘‘neurologically healthy’’ but also advanced enough in
age to minimize the possiblity of selecting a control that is at
risk of developing the disease. In this regard, collaborations
with neurologists and clinical follow-up of these patients will be
important. Comparison of disease-specific iPS cell lines to
well-characterized hES cell lines may be useful (Boulting et al.,
2011). Lastly, as it will be important to use several iPS cell lines
from multiple patients the same will be true for control lines.
Thus, the chances of phenotypic differences attributed to cell-
line-specific differences will be minimized.
Will iPS Cell Models Be a Fruitful Approach for the Study
of Adult-Onset, Sporadic Neurodegenerative Disease?
Over the next several years, an expanding collection of disease-
specific iPS cell lines will be developed for both common and
rare, monogeneic and idiopathic neurological diseases. While
the above examples confirm that iPS cell model systems can,
in certain cases, recapitulate disease-relevant phenotypes, it
remains to be seen whether iPS cell lines can be informative
for diseases with later-onset and polygenetic contributions.
Characterization of iPS cell models of monogenic forms of
neurodegenerative diseases will be important test cases for
disease modeling of more common sporadic forms, where
multiple genes in interaction with poorly defined environmental
risk factors contribute to disease. For example, in ALS, a neuro-
degenerative disorder of motor neurons leading to fatal paralysis
with an average age of onset of 50 years and death within 3–5
years of onset, only 10% of cases are familial. Among the familial
cases, mutations in SOD-1, TARDBP, and FUS account for
a significant number of patients. iPS cell lines from patients
with various mutations in SOD-1, the first identified and most
extensively characterized ALS associated gene, have been
generated and will be important resources to test whether motor
neurons develop cellular pathologies that have been described in
patient autopsy samples and transgenic mice (Boulting et al.,
2011). Any phenotypic changes found in familial ALS iPS-derived
in vitro systems could then be tested in sporadic ALS iPSmodels.
While several groups have generated iPS cell lines from
patients with other adult-onset, neurodegenerative disease
such as AD, PD, and HD, reports of spontaneous phenotypic
differences in differentiated cells from these disease-specificiPS lines has yet to emerge (Nguyen et al., 2011; Park et al.,
2008a; Seibler et al., 2011; Soldner et al., 2009; Zhang et al.,
2010). For example, iPS cell lines, generated from fibroblasts
forced to express pluripotency transcriptions factors using
a doxycycline-inducible lentiviral vector that could be subse-
quently excised with Cre-recombinase, rendering these lines
factor-free, were generated from patients with sporadic PD
and directed to differentiate into dopaminergic neurons (Soldner
et al., 2009). Using a transplantation bioassay, implanted differ-
entiated cells survived in the striatum of rats for at least 12 weeks
with a small subset of cells expressing tyrosine hydroxylase and
Girk-2 suggesting the presence of mesencephalic DA neurons.
Similarly, cell injections of differentiated cells into the striatum
of 6-hydroxydopamine (6-OHDA)-lesioned rats, a neurotoxic
lesion model of PD, similarly survived and partially corrected
amphetamine-induced rotational asymmetry suggesting a func-
tional benefit (Hargus et al., 2010). Interestingly, transplanted
dopaminergic neurons from the PD-iPS did not contain inclu-
sions of a-synuclein, a pathological hallmark of PD.
The lack of the formation of pathological aggregates in dopa-
minergic cells from sporadic PD-iPS cells gives some pause as
to whether patient-derived iPS cells from a sporadic or late-
onset disorder will show relevant phenotypes spontaneously in
the time frame of in vitro experiments or in vivo assays. It is often
argued that the time to produce disease in a patient correlates to
the predicted length it may take to recapitulate disease pheno-
types in culture. There is probably some truth to this assumption,
as evidenced by the reported successes in iPS cell disease
modeling in pediatric genetic diseases summarized previously.
Development of methods to accurately correlate how a stem
cell-derived neuron in culture correlates ontologically with the
in vivo equivalent could be useful. However, neuronal dysfunc-
tion and degeneration as a result of the neurodegenerative
process probably occurs much earlier than the initial neurolog-
ical manifestations that characterize disease. For example, prior
to the onset of the motor component of PD, a significant number
of dopaminergic neurons have already been lost. Moreover, non-
motor manifestations can predate motor manifestations by
years. In PD, one of the earliest symptoms of disease may be
olfactory and autonomic dysfunction and initial a-synuclein-
positive Lewy body pathology may occur in the dorsal motor
nucleus of the glossopharyngeal and vagal nerves and anterior
olfactory nucleus (Braak et al., 2003). It would thus seem reason-
able, in addition to studying midbrain dopaminergic neurons,
whose degeneration causes the motor component of PD, to
also consider developing directed differentiation methods from
PD-iPS cells to obtain the cell types affected earliest in the
disease.
Methods to accelerate the time to pathology in vitro will prob-
ably be important in adult-onset disease. Cellular stressors such
as oxidative stress, growth factor withdrawal, starvation, selec-
tive neurotoxins, and heat shock may help reveal differences in
iPS cell models. Taking this approach, dopaminergic neurons
from iPS cell lines of an early-onset PD patient with a known
mutation in LRRK2, demonstrated increased proportions of cas-
pase-3 activation suggesting a selective vulnerability when
exposed to a variety of cellular stressors including hydrogen
peroxide, proteosome inhibition, and 6-OHDA exposure, thoughNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 637
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neuronal cultures from PD-iPS cells expressed higher levels of
a-synuclein, as compared to the neurons from control iPS and
H9 ES cells, but whether this translated to pathological cyto-
plasmic aggregates was not discussed. Given that these results
were based on lines generated from one patient and one healthy
control, further work on additional patient and control lines is
warranted. Regardless of these limitations, similar strategies
are likely to be informative in iPS cell models of ALS, AD, and
HD (Zhang et al., 2010). In addition, developing iPS cell models
from patients with particularly aggressive, early-onset forms of
the diseasemay improve the likelihood of observing pathological
phenotypes in culture.
In addition, with better methods to direct differentiation of
pluripotent stem cells to nonneuronal cells, it may be possible
to recapitulate the relevant microenvironments that provide the
non-cell-autonomous factors that are important in several neuro-
degenerative diseases (Ilieva et al., 2009). In this regard, ES
cell-based coculture models have provided informative models
of the non-cell-autonomous effects of glia in SOD-1-related
ALS. For example, human ES cell-derived spinal motor neurons
cultured in the presence of glial cells, either derived from SOD-1
transgenic mice or primary human astrocytes genetically modi-
fied to express mutant SOD-1, are selectively vulnerable to the
toxic effects (Di Giorgio et al., 2008; Marchetto et al., 2008).
Furthermore, these culture models allowed for subsequent
searches for candidate mechanisms by which mutant glia ex-
erted their effects and testing of drugs to rescue motor neuron
death. Thus, future iPS cell-based models composed of titrated
populations of neurons, glia, and skeletal muscle to create
a functional motor unit in vitro would be informative for studies
of motor neuron disease. However, recapitulation of the full
complexity of non-cell-autonomous mechanisms in vivo may
be limited in vitro and thus correlation with established animal
models would be important. Therefore, advances in tissue engi-
neering, such as microfluidic or 3D platforms, to build more
accurate spatial and temporal microenviroments for coculture
approaches are likely to be exciting prospects for disease
modeling (Kunze et al., 2011; Majumdar et al., 2011; Park
et al., 2006; Taylor and Jeon, 2010).
Lastly, while the modeling of genetically complex neurological
disorders will be a difficult challenge, promising advances in an
iPS cell model of schizophrenia (SCZD), a complex psychiatric
disorder, gives evidence that this may be possible (Brennand
et al., 2011). Using a rabies transneuronal tracing approach,
neurons generated from iPS cell lines of four patients with
schizophrenia (SCZD-iPS) demonstrated decreased synaptic
connectivity as compared to control-iPS cell-derived neurons,
which was partially reversed by administration of the antipsy-
chotic loxapine. However, decreased connectivity did not result
in changes in synaptic function as assayed by electrophysiolog-
ical and spontaneous calcium imaging methods. Interestingly,
global analysis of gene expression changes comparing SCZD-
iPS-derived neurons to control revealed nearly 600 genes differ-
entially expressed in SCZD neurons, 25% of which were previ-
ously implicated to SCZD (Brennand et al., 2011). Comparison
of these results to phenotypes from other SCZD-iPS lines,
including rare genetically linked forms (Chiang et al., 2011), will638 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.be important next steps to validate iPS cell-based modeling of
genetically complex psychiatric disorders.
Opportunity for Drug Screens for Efficacy
and Preclinical Predictive Toxicology?
Given the potential of human pluripotent stem cells and their
differentiated cell types to model keys aspects of neurological
disease, an obvious extension of this platform is in its use for
drug discovery and predictive toxicology. As iPS cells can be
generated from different patient populations, a diversity of
drug responses and toxicity profiles could potentially be
captured. High rates of attrition of new drugs are mostly attrib-
uted to failures in clinical efficacy or unforeseen toxicities and
safety concerns, often occurring in later stages of clinical trials.
Nearly 90% of new drugs tested in humans fail to ultimately
come to clinical approval, with central nervous system disorders
as a therapeutic area, among those with the highest rate of attri-
tion (Kola and Landis, 2004). Arguably, these failures have re-
sulted from a reliance on imperfect models used during preclin-
ical development. One could envision using human pluripotent
cell-based assays in lead optimization for efficacy and also to
identify, prior to first-in-human studies, drug toxicities.
As disease-specific stem cell models for neurological
diseases continue to be validated, they are poised to become
unprecedented tools for drug discovery using human cells (Ebert
and Svendsen, 2010; Rubin, 2008). However, before their full
potential can be realized, several challenges must be overcome.
It will be critical to identify robust assays that display disease-
relevant phenotypes and are readily amenable to large-scale
drug screening. For example, high-throughput screening of
compounds that improve motor neuron survival in SMA and
ALS is one such achievable goal (Di Giorgio et al., 2008; Ebert
et al., 2009; Rubin, 2008). Thus, optimizing stem cell cultures
and differentiation protocols for large-scale, automated, multi-
well formats will be important technical goals.
Pluripotent stem cells may also find an important function in
predicting whether lead compounds identified using the cells
of a single patient will be equally effective in a large cohort of indi-
viduals. To this end, one could imagine convening a large set of
iPS cell lines, which could then be arrayed in multiwell format.
These ‘‘arrayed’’ stem cells would then be differentiated in
parallel within the multiwell format into neurons that then could
be exposed to the novel lead molecule. If the newly identified
lead compounds worked well in disease models made from
each of the genetically diverse cell lines within the array, then it
could provide additional confidence that the compound in
hand would function in a large number of patients. In turn if
compounds are found to function in the neurons of some but
not all stem cells within the array, the genetic signature of cells
that respond best can be identified. This information would
then be used to convene a clinical trial and administer the
compound only to individuals with the response genotype.
Such an approach could become a routine approach. First,
one would screen many thousands of compounds using
a disease-specific assay made from just one individual. Once
a compound is discovered, its efficacy and the generality of its
effectiveness would then be tested on neurons from the iPS
cell lines of a large number of people. Such an approach could
in principal lead to less expensive and more rapid clinical trials.
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studying predictive developmental toxicology (Laustriat et al.,
2010). A murine pluripotent stem cell-based assay (EST) evalu-
ating the toxic effects of potential compounds on ES-derived
cardiomyocytes has been validated (Genschow et al., 2002).
However, important species variation in predicting teratogenicity
exist (Nau, 1986). One notorious example in which animal testing
failed to identify teratogenic effects in humans is the case of
thalidomide, a drug prescribed to pregnant women between
1958 and 1961 for its antiemetic effects in treating morning sick-
ness, which led to an epidemic of developmental abnormalities
including limb deformities. Testing developmental neurotoxic-
ities using human pluripotent stem cells has preliminary shown
promise in modeling effects of nicotine (Zdravkovic et al.,
2008) andmethylmercury (Stummann et al., 2009). Usingmetab-
olomic profiling of cultured human ES cells and neural precursor
derivatives, it was shown that exposure to valproic acid, a widely
used antiepileptic and known human teratogen, led to identifi-
able changes in the metabolomic profile, suggesting its use in
identifying biomarkers of developmental toxicity (Cezar et al.,
2007). Furthermore, using metabolomic profiling of human ES
cells exposed to a test set of drugs with or without known tera-
togenic effects, a specific metabolomic signature correctly pre-
dicted teratogenicity in 87% of the compounds (West et al.,
2010).
Given that cardiomyocytes and hepatocytes are clinically
important cells types for drug toxicity studies, methods to direct
the differentiation of human pluripotent stem cells along these
lineages could be of tremendous value in predicting serious
adverse effects leading to drug attrition and safety concerns
(Dick et al., 2010). Electrophysiological recordings of cardiomyo-
cytes derived from human ES cells exposed to a test set of
compounds accurately predicted their known affects on QT
prolongation, a major risk factor for Torsade de Pointes and fatal
ventricular arrhythmias (Braam et al., 2010). One possible limita-
tion is the relatively immaturity of cardiomyoctes but more
mature cardiomyoctes have been obtained through better
culturing methods (Otsuji et al., 2010). Derivation of functional
hepatocytes supporting CYP1A2 and CYP3A4 metabolism has
also been successful, suggesting that iPS cell-derived hepato-
cytes may be useful in predicting differential metabolism and
toxicity of drugs (Sullivan et al., 2010).
Finally, we and many others are optimistic concerning the
prospects of using iPS cells from patients with neurological
syndromes to gain insight into their disease, as well as to
discover potential therapeutics. However, it will be critical to
keep in mind that iPS cells will be most powerfully leveraged
as tools for biomedical research when they are used alongside
existing animal, cell, and molecular models of neural degenera-
tion.
Conclusions
If disease-specific iPS cells are to be translated into clinically
informative models for mechanistic studies and therapeutic
drug discovery, several basic requirements must ideally be
met. First, it will be important to optimize methods for differenti-
ating stem cells into the particular neural cell type of interest. In
the specific case of the spinal motor neurons affected in ALS andSMA and midbrain dopaminergic neurons in PD, methods
described in mouse and human embryonic stem cells have
translated fairly well into iPS cells, though they are far from
perfect. It may further be necessary to identify culture conditions
to produce specific subclasses of the desired cell type. For
example, in ALS, selective subclasses of motor neurons degen-
erate whereas other subclasses are preferentially spared (for
example motor neurons of the oculomotor complex in the
midbrain controlling eye movements and motor neurons of
sacral spinal cord controlling bowel and bladder function). In
PD, the A9 nigrostrial dopaminergic projection neurons are pref-
erentially affected and are paramount for the motor symptoms
that typify this disorder.
Second, phenotypic assays relevant to the disease process
need to be established and advances in genetic modifications
to create isogenic control lines will impart rigorous methods to
compare disease versus control phenotypes. Needless to say,
iPS cell models alone will not be able to produce clinically impor-
tant read-outs of memory dysfunction and behavioral changes in
AD or frontotemporal dementia, tremor, bradykinesia, and
rigidity in PD, or reduced forced vital capacity, swallowing
dysfunction, dysarthria, or limb motor impairment in ALS.
However, recapitulation of key molecular, cellular, and anatom-
ical changes involved in disease are well within the scope of
disease-related phenotypes in culture. Expected phenotypes
based on previously established animal and cellular models
and observations from neuropathological studies should serve
as a means to establish hypotheses or help validate the specific
iPS model but the identification of novel mechanisms or cellular
phenotypes remains an exciting possibility. Importantly, iPS cell
models will allow for the study of human pathophysiology and
pharmacologic responses.
Lastly, iPS cell-based models may provide a new opportunity
to understand selective vulnerability of populations of neurons to
discrete degenerative stimuli, a theme common to many neuro-
logical disorders. Thus, in coming closer to creating more rele-
vant cellular models of human neurological disease, perhaps
what we can create, we can understand.
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